ICU sedation, delirium & recovery
Efficacy and safety of pantoprazole for stress-ulcer prophylaxis in critically ill patients: A systematic review and Meta-analysis of randomized controlled trials
Pooled result · Clinically important GI bleedingResult — go to the resultRelative risk 0.53 95% CI 0.29–0.94Authors' conclusion
Pantoprazole effectively reduces clinically important GI bleeding without increasing infection or overall mortality.
Study context
- Population
- Adult and pediatric ICU patients (stress-ulcer prophylaxis)
- Participants
- ≈ 9,127 participants · 7 randomized controlled trials (RCTs)
- Comparison
- Pantoprazole vs placebo
- Pantoprazolen = 4,575
- Placebon = 4,552reference
- Outcome
- Clinically important gastrointestinal (GI) bleeding
Methodological detailsPRISMA-2020, sensitivity analyses
- PRISMA-2020
- Sensitivity analyses
Pooled result
As reported in the abstract
Relative risk
0.53
95% CI 0.29–0.94
P = 0.03
Pantoprazole vs Placebo
RR 0.53 (95% CI 0.29–0.94); P = 0.03
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Overall mortality | ≈ 0.99 (0.92–1.05) | P = 0.68 | |
| 0.512Relative risk (log scale) |
Safety
Ventilator-associated pneumonia (VAP)
- Infection rates similar between groups (RR = 0.99; p = 0.78)
Clostridioides difficile infection
- Infection rates similar between groups (RR = 1.11; p = 0.73)
Original publication
Efficacy and safety of pantoprazole for stress-ulcer prophylaxis in critically ill patients: A systematic review and Meta-analysis of randomized controlled trials. J Crit Care. Published 13 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →